캡슐 블리스터 포장과 병 포장: 귀사의 제품에 어떤 것이 적합할까요?

1. 홈
2. ›
3. 블리스터 포장 기계
4. ›
5. Blister vs. Bottle Packaging for Capsules

Blister packing vs. bottle packaging: two fundamentally different protection strategies with different compliance and cost implications for capsule manufacturers.

Why the Per-Unit Cost Comparison Misleads Most Capsule Packaging Decisions

The number procurement teams look at first is exactly the wrong number. I’ve sat across from purchasing managers in Nairobi, Ho Chi Minh City, and Cairo who pulled up a spreadsheet showing bottle packaging saving $0.006 per capsule. Annual volume: 12 million units. Total saving: $72,000. They were ready to close on a bottling line.

I asked what a failed 12-month stability batch would cost. Nobody had calculated it. The API was a hygroscopic antibiotic, the distribution target was sub-Saharan Africa Zone IVb (40°C/75% RH), and the HDPE bottle specification on the table was 100cc natural with a polyfoam liner — no desiccant. That combination, in those conditions, would not get the product to end-of-shelf-life without degradation. The $72,000 saving would not survive a single regulatory inspection. It certainly would not survive a recall.

That conversation took about 45 minutes. I’m still not sure I fully convinced them. But they delayed the equipment decision, ran Zone IVb accelerated stability on both formats, and came back six weeks later. The bottle format failed at month 6. That’s the real cost. Not the $0.006.

The Correct Starting Variables for This Decision

Before comparing blister against bottle, three variables need to be locked. First: your API’s moisture vapor transmission sensitivity — specifically the moisture uptake rate (%w/w) at your worst-case distribution condition. Second: your primary target markets and their ICH climatic zones. Third: your regulatory dossier format requirements — some markets and some generics programs have specific packaging format requirements embedded in the registered dossier that make the “choice” much less open than it appears.

Get those three variables wrong and the rest of the analysis is noise. Learn more about the technical selection criteria in our guide to how to choose the right capsule blister packing machine for your pharma line.

Moisture Barrier Performance: Where Blister Packing and Bottles Diverge at the Physics Level

Standard PVC at 250 μm passes 4–6 g/m²/day. That figure matters more than any machine price. For a hygroscopic capsule fill — common in antibiotic, probiotic, and enzyme-based formulations — that transmission rate means you’re not protecting the product; you’re managing how fast it degrades.

The HDPE bottle system looks better at the container level, but the comparison is not straightforward. A well-specified 100cc HDPE bottle with induction seal and molecular sieve desiccant canister can achieve moisture ingress below 1 mg/day into the bottle headspace. The problem is distribution chain integrity: once the bottle is opened in a pharmacy or household setting, all 30 or 60 capsules are simultaneously exposed. Every opening cycle after the first resets the protection clock. In tropical retail environments — where pharmacies in Lagos or Dhaka may not have climate-controlled storage — the cumulative exposure between first opening and last capsule consumed can exceed 6 weeks.

With blister packing, each cavity is hermetically sealed independently. The 29 capsules not yet consumed remain at full protection specification regardless of when the first cavity was opened. That individual-dose isolation is not a marketing point — it’s a structural protection difference that directly correlates with end-of-shelf-life potency for moisture-sensitive APIs.

Moisture vapor transmission rate (MVTR) comparison across blister film types — the primary technical driver in the blister vs. bottle decision for moisture-sensitive capsule formulations.

MVTR Comparison Across Packaging Formats

The unit-dose isolation that blister packing provides is not a compliance checkbox — it’s the only packaging architecture that maintains full protection specification for every capsule from the moment of manufacture to the moment of consumption, regardless of where the distribution chain takes it or how many times the package has been partially accessed. For tropical markets with 40°C/75% RH conditions, that distinction is the difference between a product that arrives in specification and one that doesn’t.
— 샹 포레스터, HIJ Machinery 설립자

GMP Compliance Burden: What WHO, cGMP, and 21 CFR Actually Require from Each Format

A quality director in São Paulo called me after a ANVISA inspection in 2022. The inspector had cited the facility for inadequate container closure integrity testing documentation on a 60-count HDPE bottle SKU distributed to the Brazilian northeast — a region consistently hitting Zone IVb conditions. The product’s registered storage condition was “store below 30°C.” The CCIT protocol on file had been run at 25°C/60% RH. Nobody had run the test at the labeled worst-case condition. The dossier went back for resubmission.

That story repeats in different forms across FDA, EMA, and WHO PQ submissions. The compliance burden for bottle packaging is not lower — it’s different. Both formats require container closure integrity testing per USP <1207>. Both require stability testing at the ICH zone applicable to your distribution market. Both require equipment IQ/OQ/PQ validation. The key difference: blister packing’s individual-cavity hermetic seal makes CCIT documentation more straightforward to defend — you’re testing a sealed aluminum foil lid against a formed cavity, not the cumulative integrity of a threaded closure system under variable human torque application.

The practical compliance implication: if your product goes to Sub-Saharan Africa, Southeast Asia, or Middle Eastern markets, your regulatory team will need Zone IVb stability data — and if the bottle format fails that stability study, you have no packaging format registered for those markets. Running stability on both formats in parallel adds 6–12 months to your timeline but preserves optionality. I recommend it for any mid-sized generic manufacturer targeting more than two climatic zones.

The Real Cost Structure of Capsule Blister Packing vs. Bottle Packaging: Beyond Material Price

Of the 31 blister line projects I handled in Southeast Asia between 2018 and 2023, 11 came to me after the client had originally purchased a bottle filling line, run 12-month stability, failed the Zone IVb study, and then needed to pivot to blister. The sunk cost on those bottle lines averaged $28,000. The delay cost — in terms of product launch timeline — averaged 8 months. That’s the number I use when clients tell me blister machines are expensive.

Five-Year Total Cost of Ownership Comparison

For a full breakdown of blister line capital and operating costs, our detailed analysis at capsule blister packing machine cost breakdown for pharma buyers covers equipment tiers, tooling, and 5-year operating economics with market-specific scenarios.

Africa, Southeast Asia, and Middle East: Why Geography Changes the Blister vs. Bottle Calculus Completely

The stability report landed in March 2021. A client outside Accra had run 12-month accelerated stability on a 100-count HDPE bottle SKU of a probiotic capsule blend destined for West African pharmacy chains. Month 12 results: viable count dropped 1.8 log from label claim. The registered shelf-life was 24 months with a minimum viable count specification. They had a batch of 180,000 bottles in a Lagos warehouse. None of it could be released.

The root issue was not the formulation. The probiotic strains were stable at 25°C/60% RH for 30 months — that data existed. The issue was Zone IVb. At 40°C/75% RH, moisture ingress into the HDPE bottle headspace through the polyethylene liner was sufficient to drive water activity in the capsule fill above the threshold that triggered accelerated strain death. A PVDC/Alu blister format at the same conditions would have maintained moisture below that threshold for the full 24-month shelf-life. The MVTR numbers had predicted this outcome. Nobody had run the prediction before the batch was manufactured and shipped.

Tropical climate stability testing (Zone IVb: 40°C/75% RH) — the decisive data point for capsule packaging format selection in African, Southeast Asian, and Middle Eastern markets.

Market-by-Market Format Recommendation

Why the Blister vs. Bottle Decision Is Actually a Line Architecture Decision

포레스터 시앙

Founder, HIJ Machinery — 20 Years Pharmaceutical Packaging Equipment

💡 Forester’s Field Perspective

The choice between blister packing and bottle packaging isn’t purely aesthetic — it directly impacts your cGMP compliance posture, per-unit cost structure, and downstream market access. In my 20 years of walking production floors from São Paulo to Jakarta, I’ve watched mid-sized pharma manufacturers make this decision based solely on upfront machine price. The hidden trap? A standalone blister machine sourced from three different vendors means three different PLC protocols, zero unified FAT/SAT documentation, and a compliance nightmare when your FDA or EU auditor walks in. I’ve personally seen a $2M product launch delayed six months because the vision inspection system couldn’t communicate with the cartoning line.

Before committing to either format, lock down your URS first — define your target markets, moisture sensitivity requirements, and annual output. At HIJ, we always push for a turnkey integration approach: one supplier, one validated data chain, zero inter-vendor finger-pointing. That’s not a sales pitch. That’s 20 years of watching projects fail the other way. Our turnkey packaging solutions approach exists precisely because the equipment decision and the line architecture decision are not separable.

When a client asks me “blister or bottle,” my first question is always: “Who else are you buying equipment from?” The answer shapes everything. A fully integrated blister line — capsule filler feeding directly into a DPP-260 blister packer with a matched cartoning line — has a single FAT protocol, a single qualified supplier for spare parts, and a single point of accountability when something goes wrong during IQ/OQ/PQ. That structure is not just convenient. It is what makes your validation dossier defensible in front of a WHO inspector or an FDA 483 response.

The same logic applies to 태블릿 블리스터 포장기 selections: the format decision and the line integration decision must be made simultaneously. Choosing equipment in isolation creates gaps that show up six months later as compliance deficiencies or production bottlenecks — neither of which is cheap to fix after commissioning.

A fully integrated capsule blister packing line: upstream capsule filling, blister forming/sealing, vision inspection, and cartoning under a single validated FAT/SAT protocol — the architecture that eliminates inter-vendor compliance gaps.

Output Rates, Changeover Time, and Scalability: Which Format Fits Your Production Model?

Output rate comparisons between the two formats depend heavily on fill count configuration. A 10-cavity blister card at 150 cards/min gives you 1,500 capsules/min packaged into unit-dose cards. A 60-count bottle line at 120 bottles/min gives you 7,200 capsules/min into bottles. Those numbers favor bottles at face value — until you factor in the downstream cartoning and labeling steps.

A blister line with integrated cartoning typically processes cards directly from punching station into carton at the same cycle rate. A bottle line requires filling, capping, induction sealing, labeling, and cottoning or desiccant insertion as separate sequential steps. The net packaged-unit output per labor hour is closer between the two formats than the raw machine speeds suggest — typically within 15–25% when the full secondary packaging step count is included in the comparison.

Changeover time is the other variable most production planners underweight. A blister format change requires mold change, film roll change, and sealing station adjustment — typically 45–90 minutes for a trained operator on a well-maintained machine. A bottle format change requires adjustment of filling heads, capper chuck sizing, and label format programming — typically 30–60 minutes. For facilities running 6+ SKUs, this difference compounds into meaningful OEE impact over a year.

The Format Decision Framework: A Practical Guide for Capsule Manufacturers by Buyer Type

I won’t tell you this decision is simple. It involves your API profile, your target markets, your validation timeline, and sometimes your relationship with the regulatory reviewer who will evaluate your dossier. What I can give you is a framework that has worked across 20 years of projects.

• ▶
  Startup generic pharma (<$5M revenue, first GMP line): Blister packing. The validation documentation structure is more standardized, the individual-cavity hermetic seal makes CCIT straightforward, and the format gives you maximum market access flexibility as your product portfolio expands. The $15,000–$25,000 CapEx premium over a bottle line is your insurance against stability failures that could cost 10x more to remediate.
• ▶
  Mid-size generic manufacturer (established, 3–8 SKUs, Zone IVb distribution): Blister packing — PVDC or Alu-Alu depending on API sensitivity. Your regulatory dossiers in tropical markets almost certainly require Zone IVb stability data. If you don’t already have it for your bottle format, running it now will take 12–18 months and cost $15,000–$30,000 per product. Starting with blister packing eliminates that risk category entirely.
• ▶
  OTC nutraceutical / wellness brand (domestic market, vitamin/mineral capsules): Bottles are likely adequate and economically superior. Zone I/II stability data for standard multivitamin or mineral formulations consistently passes in HDPE bottle with induction seal. The per-unit material cost advantage compounds meaningfully at 50+ million units per year.
• ▶
  Contract manufacturer (CMO/CDMO, multi-client multi-format): Both — but integrate them on a single line architecture with format-change documentation. A blister-capable line that can also run bottle formats via quick-change tooling gives CMOs the flexibility to serve regulated and nutraceutical clients on the same platform. This is a capital efficiency argument, not a quality one.
• ▶
  EPC contractor / turnkey project engineer: Specify the packaging format in the URS before any equipment is sourced. Your client’s regulatory affairs team should sign off on the format decision before you issue a single RFQ. If that sign-off doesn’t happen and the stability data comes back negative after equipment procurement, the project timeline is broken and nobody wins.

For buyers at the stage of evaluating specific machine configurations and output specifications, our 캡슐 블리스터 포장기 제품 페이지 covers the DPP-260’s full technical specification, available cavity configurations, and integration options for turnkey pharmaceutical lines.